Back to search results

Observational Study of the Pediatric Evolutionary Tumor Board (pedsETB) for Pediatric Cancer

This study is looking at how well a team of experts, called the Pediatric Evolutionary Tumor Board (pedsETB), can come up with new treatment ideas for children and young adults with cancer. This team includes doctors, scientists, and other specialists. The pedsETB will develop additional treatment strategies for patients who don't have many curative options or haven't responded well to previous treatments. The study aims to see if the pedsETB can successfully create these strategies. You might be able to join if your cancer is considered unlikely to be cured by standard treatments, or if you've had a relapse, are at high risk of recurrence, or haven't responded well to past therapies. The study is currently unclear on its recruitment status and plans to include 35 participants.

Study design
This is an observational study that plans to include 35 participants. It is not a drug trial, but rather evaluates the pedsETB intervention.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will measure the feasibility of the pedsETB developing therapeutic strategies from baseline up to 60 months (5 years) from the end of therapy.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06423950

Generating Novel Translational and Therapeutic Strategies Based on a Multicenter, Pediatric and AYA Evolutionary Tumor Board (pedsETB)

Recruiting
Not specifiedAll AgesObservational
H. Lee Moffitt Cancer Center and Research Institute
~35 participants
Updated 2026-09-03 on ClinicalTrials.gov
What's tested:Peds Evolutionary Tumor Board (pedsETB)

At a glance

Recruiting sites
3 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The feasibility of the pedsETB developing therapeutic strategies
Measured over Baseline to up to 60 months from end of therapy

Conditions

Pediatric Cancer

Explore related trials

Childhood Malignant Neoplasm

Where it's being run

3 sites across 3 states
Connecticut1
Florida1
New York1

Study leadership

  • Jonathan Metts, MD · PRINCIPAL_INVESTIGATOR · Moffitt Cancer Center

Who to contact

Jessica Crimella
[email protected]
813-745-6250
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participant must be considered likely incurable given the standard of care. This is inclusive of patients newly diagnosed, relapsed or in remission but at high risk of recurrence, with suboptimal responses to previous therapy, or with many potentially beneficial, but unlikely curative options for care.
Participant must have an age-appropriate performance status: Karnofsky 50 or more for patients 16 years of age or older OR Lansky score of 50 or more for patients less than16 years of age.
Participant and/or parents or legal guardian and primary oncologist must be willing to consider the therapeutic strategies recommended by the pedsETB.
Participant must be willing to be followed over time and allow collection of clinical data including scans, available blood and lab samples, and optional pedsETB serial blood sampling.
All Participants and/or their parents or legal guardians must have the ability to understand and the willingness to sign a written informed consent or assent document.

Exclusion

Participants without known therapies to reliably induce a response are excluded from pedsETB and should seek clinical trials.

What this trial measures

  • The feasibility of the pedsETB developing therapeutic strategiesBaseline to up to 60 months from end of therapy

    The investigators will measure the ability of a multidisciplinary group, the pedsETB, to develop additional therapeutic strategies in patients without curative options. The investigators plan to enroll 35 patients on the study. The primary objective will be successfully met if the pedsETB can develop an evolutionary based therapeutic strategy that differs from the oncologist's opinion prior to presentation for at least 80%, or 28 of these patients.